Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
27 results
D1.264 - Assessment by general practitioners of a therapeutic patient education guide for allergic patients
D1.262 - Clinical significance of a basophil activation test for Japanese beekeepers naturally sensitized to honey bee venom
D1.265 - Component-Resolved Diagnosis and Clinical Profiles of Anisakis Allergy in Japan
D1.266 - Investigation of anaphylaxis in mastocytosis mouse models
D1.267 - Recurrence of perioperative anaphylaxis: analysis of a multicenter cohort
D1.268 - The endothelial glycocalyx as a therapeutic target in anaphylaxis
D1.269 - Deciphering cardiovascular profiles in sera and extracellular vesicles from anaphylactic patients. Impact in endothelial cells
D1.270 - Anaphylaxis and Adrenaline: Knowledge gaps with critical consequences
D1.271 - Bovine gelatine-induced anaphylaxis brought on by eating beef, sweets containing gelatin, and medications
D1.272 - Efficacy and Safety of Omalizumab in Treating Severe Allergic Reactions with Urticaria as the Initial Symptom
D1.273 - Anaphylactic Reaction Following Sulphur Hexafluoride Administration
D1.422 - A service review of the complex COVID-19 vaccination service
D1.425 - Familial Cold Autoinflammatory Syndrome Post COVID-19 Vaccine: A Case Report
D1.423 - Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic
D1.424 - Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic
D1.426 - Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download